Compare AST SpaceMobile Inc (ASTS) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AST SpaceMobile Inc vs Summit Therapeutics Inc — how do they compare? AST SpaceMobile Inc trades at $72.33 (market cap $21.90B), while Summit Therapeutics Inc trades at $15.2 (market cap $11.84B). The key difference: AST SpaceMobile Inc is the larger of the two by market cap, and AST SpaceMobile Inc is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| ASTS | SMMT | |
|---|---|---|
Market Cap | $21.90B | $11.84B |
Sector | Media | Health |
52-Week High | $133.09 | $29.32 |
52-Week Low | $36.91 | $13.05 |
Enterprise Value | $21.87B | $11.26B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASTS trades at $73.32, down 0.76% on the day, with a bearish technical signal from moving averages and mixed oscillators. The company reported revenue of $70.92 million in 2025 but sustained a net loss of $341.94 million, missing earnings expectations for three consecutive quarters. Recent news highlights potential in defense communications via satellite technology, though competition with SpaceX remains a focal point.
The outlook is speculative with high execution risk; analyst consensus is divided with a $90.33 price target. Investment opportunity hinges on successful satellite deployment and partnership execution, but persistent losses and intense competition pose significant downside risks for shareholders.
Summit Therapeutics (SMMT) trades at $15.25, down 1.49% today, with technical indicators showing bearish momentum despite recent positive clinical trial results for its lead oncology drug ivonescimab. The company reported a net loss of $1.08 billion in 2025, with negative ROE and ROA, while cash flow trends show increasing operational cash burn. Analyst consensus remains bullish with 14 buy ratings and a $15.57 price target, reflecting optimism around the drug's potential despite financial challenges.
SMMT presents a high-risk, high-reward opportunity centered on binary clinical outcomes. Near-term catalysts include FDA review of ivonescimab, but substantial financial losses and dependence on a single asset create significant volatility. The stock's outlook hinges entirely on successful drug commercialization, with current valuations disconnected from fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AST SpaceMobile Inc
AST SpaceMobile Inc is a satellite designer and manufacturer. The company is building the global cellular broadband network in space to operate directly with standard, unmodified mobile devices based on extensive IP and patent portfolio. AST is on a mission to eliminate the connectivity gaps faced by mobile subscribers and finally bring broadband to the billions who remain unconnected.
Read more on ASTS →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
